CNS Pharmaceuticals (CNSP) Competitors

CNS Pharmaceuticals logo
$4.26 +0.11 (+2.67%)
Closing price 03:58 PM Eastern
Extended Trading
$4.26 0.00 (-0.02%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CNSP vs. PTPI, TAOX, CRVO, COCP, and TXMD

Should you buy CNS Pharmaceuticals stock or one of its competitors? CNS Pharmaceuticals's main competitors and comparable companies include Petros Pharmaceuticals (PTPI), Synaptogenix (TAOX), CervoMed (CRVO), Cocrystal Pharma (COCP), and TherapeuticsMD (TXMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CNS Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Petros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, CNS Pharmaceuticals had 2 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 2 mentions for CNS Pharmaceuticals and 0 mentions for Petros Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 1.89 beat Petros Pharmaceuticals' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
CNS Pharmaceuticals Very Positive
Petros Pharmaceuticals Neutral

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 1.8% of CNS Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CNS PharmaceuticalsN/AN/A-$15.85M-$23.59N/A
Petros Pharmaceuticals$5.11M0.02-$8.16M-$0.36N/A

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CNS PharmaceuticalsN/A -210.32% -136.14%
Petros Pharmaceuticals N/A -78.22%-23.50%

CNS Pharmaceuticals has a beta of 3.21, indicating that its stock price is 221% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

Summary

Petros Pharmaceuticals beats CNS Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Synaptogenix?

CNS Pharmaceuticals (NASDAQ:CNSP) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

CNS Pharmaceuticals has higher earnings, but lower revenue than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CNS PharmaceuticalsN/AN/A-$15.85M-$23.59N/A
Synaptogenix$300K50.12-$28.74M-$3.85N/A

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 1.8% of CNS Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, CNS Pharmaceuticals had 1 more articles in the media than Synaptogenix. MarketBeat recorded 2 mentions for CNS Pharmaceuticals and 1 mentions for Synaptogenix. CNS Pharmaceuticals' average media sentiment score of 1.89 beat Synaptogenix's score of 0.26 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
CNS Pharmaceuticals Very Positive
Synaptogenix Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CNS Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Synaptogenix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

CNS Pharmaceuticals has a beta of 3.21, indicating that its stock price is 221% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market.

CNS Pharmaceuticals has a net margin of 0.00% compared to Synaptogenix's net margin of -768.22%. Synaptogenix's return on equity of -68.93% beat CNS Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CNS PharmaceuticalsN/A -210.32% -136.14%
Synaptogenix -768.22%-68.93%-50.44%

Summary

CNS Pharmaceuticals beats Synaptogenix on 6 of the 11 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to CervoMed?

CervoMed (NASDAQ:CRVO) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

In the previous week, CervoMed had 4 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 6 mentions for CervoMed and 2 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 1.89 beat CervoMed's score of 0.63 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CervoMed
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CNS Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

CervoMed has a beta of -0.62, indicating that its stock price is 162% less volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.21, indicating that its stock price is 221% more volatile than the broader market.

25.2% of CervoMed shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 35.8% of CervoMed shares are owned by insiders. Comparatively, 1.8% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CervoMed presently has a consensus price target of $21.00, indicating a potential upside of 1,300.00%. Given CervoMed's stronger consensus rating and higher probable upside, research analysts plainly believe CervoMed is more favorable than CNS Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CervoMed
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
CNS Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

CervoMed's return on equity of -164.95% beat CNS Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CervoMedN/A -164.95% -133.71%
CNS Pharmaceuticals N/A -210.32%-136.14%

CNS Pharmaceuticals has lower revenue, but higher earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CervoMed$4.01M5.66-$26.97M-$2.77N/A
CNS PharmaceuticalsN/AN/A-$15.85M-$23.59N/A

Summary

CervoMed beats CNS Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Cocrystal Pharma?

CNS Pharmaceuticals (NASDAQ:CNSP) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

In the previous week, Cocrystal Pharma had 6 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 8 mentions for Cocrystal Pharma and 2 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 1.89 beat Cocrystal Pharma's score of -0.39 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CNS Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Cocrystal Pharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CNS Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cocrystal Pharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Cocrystal Pharma is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CNS PharmaceuticalsN/AN/A-$15.85M-$23.59N/A
Cocrystal PharmaN/AN/A-$8.83M-$0.76N/A

CNS Pharmaceuticals has a beta of 3.21, suggesting that its share price is 221% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 1.8% of CNS Pharmaceuticals shares are owned by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CNS Pharmaceuticals' return on equity of -210.32% beat Cocrystal Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
CNS PharmaceuticalsN/A -210.32% -136.14%
Cocrystal Pharma N/A -295.88%-156.05%

Summary

Cocrystal Pharma beats CNS Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

TherapeuticsMD has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TherapeuticsMD$3.02M7.32-$570K$0.0295.50
CNS PharmaceuticalsN/AN/A-$15.85M-$23.59N/A

TherapeuticsMD has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.21, meaning that its share price is 221% more volatile than the broader market.

In the previous week, TherapeuticsMD and TherapeuticsMD both had 2 articles in the media. CNS Pharmaceuticals' average media sentiment score of 1.89 beat TherapeuticsMD's score of 1.61 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TherapeuticsMD
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
CNS Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

TherapeuticsMD has a net margin of 3.26% compared to CNS Pharmaceuticals' net margin of 0.00%. TherapeuticsMD's return on equity of 0.57% beat CNS Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
TherapeuticsMD3.26% 0.57% 0.41%
CNS Pharmaceuticals N/A -210.32%-136.14%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TherapeuticsMD
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CNS Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 1.8% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

TherapeuticsMD beats CNS Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Get CNS Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CNSP vs. The Competition

MetricCNS PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$6.22M$13.36B$7.60B$11.73B
Dividend YieldN/A2.58%2.47%4.47%
P/E Ratio-0.2428.2033.6629.94
Price / SalesN/A7.078.305.63
Price / CashN/A15.6321.0121.90
Price / Book0.585.404.443.72
Net Income-$15.85M$2.88B$3.51B$393.84M
7 Day Performance13.14%-5.15%-6.49%-6.02%
1 Month Performance-13.02%-4.73%-4.89%-7.35%
1 Year Performance-36.59%-7.27%-1.65%-7.46%

CNS Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNSP
CNS Pharmaceuticals
0.9155 of 5 stars
$4.26
+2.7%
N/A-38.1%$6.22MN/AN/A8
PTPI
Petros Pharmaceuticals
N/A$0.00
-3.0%
N/A-79.3%$100K$5.11MN/A20
TAOX
Synaptogenix
0.6396 of 5 stars
$2.58
-5.1%
N/A-70.7%$21.88M$300KN/A4
CRVO
CervoMed
2.3616 of 5 stars
$1.37
-4.2%
$21.00
+1,432.8%
-81.7%$21.63M$4.01MN/A15
COCP
Cocrystal Pharma
0.6847 of 5 stars
$1.03
-6.8%
N/A-1.0%$21.29MN/AN/A10

Related Companies and Tools


This page (NASDAQ:CNSP) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners